Perpetua Medical (PERP) Q2 2026 earnings summary

Executive summary

• Net sales for Q2 2026 rose 121% year-over-year to 5,963 KSEK, driven by the Spirotronic acquisition and growth at ES Medical.

• Operating loss widened to -3,095 KSEK in Q2 2026 from -538 KSEK a year earlier, mainly due to higher expenses from acquisitions and product development.

• Cash and cash equivalents at quarter-end were 16,828 KSEK, up from 5,989 KSEK last year.

• The company is actively pursuing further acquisitions and developing proprietary products in its subsidiaries.

Financial highlights

• Q2 2026 net revenue: 5,963 KSEK (Q2 2025: 2,700 KSEK); H1 2026 net sales: 10,943 KSEK (H1 2025: 5,927 KSEK).

• Q2 2026 operating loss: -3,095 KSEK (Q2 2025: -538 KSEK); H1 2026 operating loss: -5,861 KSEK (H1 2025: -1,972 KSEK).

• Q2 2026 EPS: -0.36 SEK (Q2 2025: -0.16 SEK); H1 2026 EPS: -0.69 SEK (H1 2025: -0.44 SEK).

• Q2 2026 cash flow: -3,456 KSEK (Q2 2025: -1,224 KSEK); H1 2026 cash flow: 12,495 KSEK (H1 2025: -3,411 KSEK).

• Equity at 30 June 2026: 25,467 KSEK (30 June 2025: 8,912 KSEK); equity ratio: 44% (55%).

Outlook and guidance

• Management expects further growth through additional acquisitions and proprietary product launches.

• Ongoing negotiations with several acquisition targets could result in near-term transactions.

• ES Medical is preparing to launch its first proprietary product in H2 2026.

• Spirotronic is targeting integration of its components into next-generation ventilators.